Altered Regulation of the Glucose Transporter GLUT3 in PRDX1 Null Cells Caused Hypersensitivity to Arsenite

Reem Ali(Hamad bin Khalifa University), Dindial Ramotar(Université de Montréal), Gordon McKay(Hamad bin Khalifa University), Mashael Algethami(University of Nottingham), Essam M. Abdelalim(Qatar Airways (Qatar)), Mustapha Aouida(Hamad bin Khalifa University), Bushra Memon(Technology Innovation Institute), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Singdhendubala Pradhan(Hamad bin Khalifa University), Abdallah Alhaj Sulaiman(Hamad bin Khalifa University)
Cells
November 22, 2023
10.3390/cells12232682
Cited by 9

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Production and applications of activated carbons as adsorbents from olive stones
|Biomass Conversion and Biorefinery|2019|474
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374